Angiotensin II Type 1 Receptor Blockers

"Angiotensin II Type 1 Receptor Blockers" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus, MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure, which enables searching at various levels of specificity.

MeSH information

Definition | Details | More General Concepts | Related Concepts | More Specific Concepts

Agents that antagonize ANGIOTENSIN II TYPE 1 RECEPTOR. Included are ANGIOTENSIN II analogs such as SARALASIN and biphenylimidazoles such as LOSARTAN. Some are used as ANTIHYPERTENSIVE AGENTS.

Descriptor ID	D047228
MeSH Number(s)	D27.505.519.162.500
Concept/Terms	Angiotensin II Type 1 Receptor Blockers Angiotensin II Type 1 Receptor Blockers Angiotensin II Type 1 Receptor Antagonists Type 1 Angiotensin Receptor Blockers Angiotensin 2 Type 1 Receptor Antagonists Type 1 Angiotensin Receptor Antagonists Selective Angiotensin II Receptor Antagonists Selective Angiotensin II Receptor Antagonists Sartans

Below are MeSH descriptors whose meaning is more general than "Angiotensin II Type 1 Receptor Blockers".

Chemicals and Drugs [D]
Chemical Actions and Uses [D27]
Pharmacologic Actions [D27.505]
Molecular Mechanisms of Pharmacological Action [D27.505.519]
Angiotensin Receptor Antagonists [D27.505.519.162]
Angiotensin II Type 1 Receptor Blockers [D27.505.519.162.500]

Below are MeSH descriptors whose meaning is related to "Angiotensin II Type 1 Receptor Blockers".

Below are MeSH descriptors whose meaning is more specific than "Angiotensin II Type 1 Receptor Blockers".

publications

Timeline | Most Recent

This graph shows the total number of publications written about "Angiotensin II Type 1 Receptor Blockers" by people in this website by year, and whether "Angiotensin II Type 1 Receptor Blockers" was a major or minor topic of these publications.

Bar chart showing 3 publications over 3 distinct years, with a maximum of 1 publications in 2010 and 2013 and 2018

To see the data from this visualization as text, click here.

Year	Minor Topic	Total
2010	1	1
2013	1	1
2018	1	1

Below are the most recent publications written about "Angiotensin II Type 1 Receptor Blockers" by people in Profiles.

Silva LS, Peruchetti DB, Silva-Aguiar RP, Abreu TP, Dal-Cheri BKA, Takiya CM, Souza MC, Henriques MG, Pinheiro AAS, Caruso-Neves C. The angiotensin II/AT1 receptor pathway mediates malaria-induced acute kidney injury. PLoS One. 2018; 13(9):e0203836.

View in: PubMed
Fan X, Song X, Zhao M, Jarskog LF, Natarajan R, Shukair N, Freudenreich O, Henderson DC, Goff DC. The effect of adjunctive telmisartan treatment on psychopathology and cognition in patients with schizophrenia. Acta Psychiatr Scand. 2017 11; 136(5):465-472.

View in: PubMed
Vohra R, Accorsi A, Kumar A, Walter G, Girgenrath M. Magnetic Resonance Imaging Is Sensitive to Pathological Amelioration in a Model for Laminin-Deficient Congenital Muscular Dystrophy (MDC1A). PLoS One. 2015; 10(9):e0138254.

View in: PubMed
Silva-Filho JL, Souza MC, Ferreira-Dasilva CT, Silva LS, Costa MF, Padua TA, Henriques Md, Morrot A, Savino W, Caruso-Neves C, Pinheiro AA. Angiotensin II is a new component involved in splenic T lymphocyte responses during Plasmodium berghei ANKA infection. PLoS One. 2013; 8(4):e62999.

View in: PubMed
Appel LJ, Wright JT, Greene T, Agodoa LY, Astor BC, Bakris GL, Cleveland WH, Charleston J, Contreras G, Faulkner ML, Gabbai FB, Gassman JJ, Hebert LA, Jamerson KA, Kopple JD, Kusek JW, Lash JP, Lea JP, Lewis JB, Lipkowitz MS, Massry SG, Miller ER, Norris K, Phillips RA, Pogue VA, Randall OS, Rostand SG, Smogorzewski MJ, Toto RD, Wang X. Intensive blood-pressure control in hypertensive chronic kidney disease. N Engl J Med. 2010 Sep 02; 363(10):918-29.

View in: PubMed
Nguyen HL, Goldberg RJ, Gore JM, Fox KA, Eagle KA, Gurfinkel EP, Spencer FA, Reed G, Quill A, Anderson FA. Age and sex differences, and changing trends, in the use of evidence-based therapies in acute coronary syndromes: perspectives from a multinational registry. Coron Artery Dis. 2010 Sep; 21(6):336-44.

View in: PubMed
Zile MR, Gaasch WH, Anand IS, Haass M, Little WC, Miller AB, Lopez-Sendon J, Teerlink JR, White M, McMurray JJ, Komajda M, McKelvie R, Ptaszynska A, Hetzel SJ, Massie BM, Carson PE. Mode of death in patients with heart failure and a preserved ejection fraction: results from the Irbesartan in Heart Failure With Preserved Ejection Fraction Study (I-Preserve) trial. Circulation. 2010 Mar 30; 121(12):1393-405.

View in: PubMed
Aslam F, Haque A, Agostini JV, Wang Y, Foody JM. Hypertension prevalence and prescribing trends in older US adults: 1999-2004. J Clin Hypertens (Greenwich). 2010 Feb 01; 12(2):75-81.

View in: PubMed
Jiang N, Shi P, Li H, Lu S, Braseth L, Cuadra AE, Raizada MK, Sumners C. Phosphate-activated glutaminase-containing neurons in the rat paraventricular nucleus express angiotensin type 1 receptors. Hypertension. 2009 Oct; 54(4):845-51.

View in: PubMed
Goldberg RJ, Darling C, Joseph B, Saczynski J, Chinali M, Lessard D, Pezzella S, Spencer FA. Epidemiology of decompensated heart failure in a single community in the northeastern United States. Am J Cardiol. 2009 Aug 01; 104(3):377-82.

View in: PubMed

People

Explore

Similar Concepts

Top Journals